BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36612009)

  • 1. Pathologic Response of Associated Ductal Carcinoma In Situ to Neoadjuvant Systemic Therapy: A Systematic Review.
    Wazir U; Patani N; Balalaa N; Mokbel K
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.
    Ploumen RAW; de Mooij CM; Gommers S; Keymeulen KBMI; Smidt ML; van Nijnatten TJA
    Eur Radiol; 2023 Aug; 33(8):5423-5435. PubMed ID: 37020070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
    Groen EJ; van der Noordaa MEM; Schaapveld M; Sonke GS; Mann RM; van Ramshorst MS; Lips EH; Vrancken Peeters MTFD; van Duijnhoven FH; Wesseling J
    Breast Cancer Res Treat; 2021 Aug; 189(1):213-224. PubMed ID: 33945043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis.
    Ploumen RAW; Claassens EL; Kooreman LFS; Keymeulen KBMI; van Kats MACE; Gommers S; Siesling S; van Nijnatten TJA; Smidt ML
    Breast Cancer Res Treat; 2023 Sep; 201(2):227-235. PubMed ID: 37395816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
    Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
    Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy may eradicate ductal carcinoma in situ (DCIS) but not the associated microcalcifications.
    Goldberg H; Zandbank J; Kent V; Leonov-Polak M; Livoff A; Chernihovsky A; Guindy M; Evron E
    Eur J Surg Oncol; 2017 Aug; 43(8):1415-1420. PubMed ID: 28526187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical outcomes and prognosis of HER2+ invasive breast cancer patients with a DCIS component treated with breast-conserving surgery after neoadjuvant systemic therapy.
    Ploumen RAW; Claassens EL; Kooreman LFS; Keymeulen KBMI; van Kats MACE; van Kuijk SMJ; Siesling S; van Nijnatten TJA; Smidt ML
    Eur J Surg Oncol; 2024 Jun; 50(9):108465. PubMed ID: 38870869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.
    van la Parra RFD; Tadros AB; Checka CM; Rauch GM; Lucci A; Smith BD; Krishnamurthy S; Valero V; Yang WT; Kuerer HM
    Br J Surg; 2018 Apr; 105(5):535-543. PubMed ID: 29465744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Intraoperative Radiotherapy for the Management of Ductal Carcinoma In Situ of the Breast.
    Rivera R; Banks A; Casillas-Lopez A; Rashtian A; Lewinsky B; Sheth P; Hovannesian-Larsen L; Brousseau D; Iyengar G; Holmes DR
    Breast J; 2016; 22(1):63-74. PubMed ID: 26534876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma.
    Jones RL; Lakhani SR; Ring AE; Ashley S; Walsh G; Smith IE
    Br J Cancer; 2006 Feb; 94(3):358-62. PubMed ID: 16421590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
    Santamaría G; Bargalló X; Fernández PL; Farrús B; Caparrós X; Velasco M
    Radiology; 2017 Jun; 283(3):663-672. PubMed ID: 27875106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy.
    Um E; Kang JW; Lee S; Kim HJ; Yoon TI; Sohn G; Chung IY; Kim J; Lee JW; Son BH; Ahn SH; Ko BS
    Clin Breast Cancer; 2018 Oct; 18(5):e1087-e1091. PubMed ID: 29703689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast surgery after neoadjuvant systemic therapy.
    Pawloski KR; Barrio AV
    Transl Breast Cancer Res; 2024; 5():13. PubMed ID: 38751679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant systemic therapy does not compromise local control after breast-conserving surgery: a single-center, propensity score matching study in China.
    Yang F; Wu SY; Mo M; Xiao Q; Yang X; Liu YY; Li JW; Shao ZM; Liu GY
    Transl Cancer Res; 2020 Jan; 9(1):155-165. PubMed ID: 35117169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
    Mazouni C; Peintinger F; Wan-Kau S; Andre F; Gonzalez-Angulo AM; Symmans WF; Meric-Bernstam F; Valero V; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2007 Jul; 25(19):2650-5. PubMed ID: 17602071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
    Mohapatra M; Sarma YS
    J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response.
    Santamaría G; Bargalló X; Ganau S; Alonso I; Muñoz M; Mollà M; Fernández PL; Prat A
    Eur J Radiol; 2019 Aug; 117():132-139. PubMed ID: 31307638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of lumpectomy surface with large field-of-view confocal laser scanning microscope for intraoperative margin assessment - POLARHIS study.
    Sandor MF; Schwalbach B; Hofmann V; Istrate SE; Schuller Z; Ionescu E; Heimann S; Ragazzi M; Lux MP
    Breast; 2022 Dec; 66():118-125. PubMed ID: 36240525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reoperation Rates in Ductal Carcinoma In Situ vs Invasive Breast Cancer After Wire-Guided Breast-Conserving Surgery.
    Langhans L; Jensen MB; Talman MM; Vejborg I; Kroman N; Tvedskov TF
    JAMA Surg; 2017 Apr; 152(4):378-384. PubMed ID: 28002557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.